ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

31 Jan 2024 13:01:00 By Nasdaq GlobeNewswire

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

29 Jan 2024 05:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Introduces Vision 2030

07 Jan 2024 14:45:29 By Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

28 Dec 2023 13:15:00 By Nasdaq GlobeNewswire

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

20 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

19 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

11 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

29 Nov 2023 01:30:39 By Nasdaq GlobeNewswire

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism

20 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

15 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Reports Third Quarter 2023 Financial Results

07 Nov 2023 13:01:02 By Nasdaq GlobeNewswire

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

31 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

16 Oct 2023 13:01:00 By Nasdaq GlobeNewswire

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

02 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

23 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

14 Sep 2023 09:22:57 By Nasdaq GlobeNewswire

Ascendis Pharma Reports Second Quarter 2023 Financial Results

05 Sep 2023 13:03:00 By Nasdaq GlobeNewswire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

05 Sep 2023 13:01:00 By Nasdaq GlobeNewswire

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

05 Sep 2023 13:01:00 By Nasdaq GlobeNewswire